Ropes & Gray: Erasca Announces Strategic In-Licensing of RAS Mutation Targeting Oncology Program
May 21, 2024
May 21, 2024
BOSTON, Massachusetts, May 21 -- Ropes and Gray, a law firm, issued the following news:
Ropes & Gray advised Erasca, Inc., a precision oncology company, in an exclusive license agreement for a pre-clinical RAS mutation targeting program with a potent oral tumor inhibitor, a potential best-in-class pan-RAS molecular glue called ERAS-0015. The transaction was announced on May 16.
Under the license agreement, in exchange for an exclusive license to develop and commerci . . .
Ropes & Gray advised Erasca, Inc., a precision oncology company, in an exclusive license agreement for a pre-clinical RAS mutation targeting program with a potent oral tumor inhibitor, a potential best-in-class pan-RAS molecular glue called ERAS-0015. The transaction was announced on May 16.
Under the license agreement, in exchange for an exclusive license to develop and commerci . . .